GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Cyclically Adjusted Book per Share

Novartis AG (Novartis AG) Cyclically Adjusted Book per Share : $30.53 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2024 was $19.445. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $30.53 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -0.70% per year. And the median was 3.45% per year.

As of today (2024-04-27), Novartis AG's current stock price is $96.00. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $30.53. Novartis AG's Cyclically Adjusted PB Ratio of today is 3.14.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.76.


Novartis AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.53 30.26 29.72 30.91 32.84

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.98 30.15 30.69 32.84 30.53

Competitive Comparison of Novartis AG's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=19.445/106.4611*106.4611
=19.445

Current CPI (Mar. 2024) = 106.4611.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 29.014 101.517 30.427
201409 29.491 101.247 31.010
201412 29.503 100.704 31.190
201503 31.556 100.339 33.481
201506 32.612 100.464 34.559
201509 32.018 99.785 34.160
201512 32.456 99.386 34.766
201603 30.157 99.475 32.275
201606 30.428 100.088 32.366
201609 31.566 99.604 33.739
201612 31.521 99.380 33.767
201703 28.570 100.040 30.404
201706 29.843 100.285 31.681
201709 31.203 100.254 33.135
201712 32.004 100.213 33.999
201803 30.504 100.836 32.206
201806 33.084 101.435 34.723
201809 33.739 101.246 35.477
201812 34.015 100.906 35.888
201903 20.333 101.571 21.312
201906 22.439 102.044 23.410
201909 23.193 101.396 24.352
201912 24.492 101.063 25.800
202003 22.241 101.048 23.433
202006 23.509 100.743 24.843
202009 23.954 100.585 25.353
202012 25.079 100.241 26.635
202103 22.504 100.800 23.768
202106 24.161 101.352 25.379
202109 25.377 101.533 26.609
202112 30.272 101.776 31.666
202203 27.813 103.205 28.690
202206 28.828 104.783 29.290
202209 28.275 104.835 28.714
202212 27.997 104.666 28.477
202303 24.825 106.245 24.876
202306 25.068 106.576 25.041
202309 18.567 106.570 18.548
202312 22.831 106.461 22.831
202403 19.445 106.461 19.445

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Novartis AG  (OTCPK:NVSEF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=96.00/30.53
=3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.76.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.